Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. - Wikidata - awgldk - TriplyDB

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33380246

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Role of the tumor microenvironment in mature B-cell lymphoid malignancies The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions Lymphoma Immunotherapy: Current Status Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary Lenalidomide for the treatment of B-cell lymphoma.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.Thalidomide-a notorious sedative to a wonder anticancer drug.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.

P2860

Q21198872-93A7B8FA-3C97-49D8-8A1F-40A5362BFFF3 Q21285161-072171D8-751B-4772-8FCF-73F52B67BAD5 Q24597424-8AF01935-EC77-44F0-8BC2-AE5EB7ED4DAA Q24607479-7C8506B3-F21C-426E-9DF2-876AE7A600FF Q26748775-49C83DCE-B037-4E85-AFFA-B80D3A180D8C Q26772907-4342953B-0AA5-41B8-B7BF-AABCB52B0487 Q26781831-2706F9DE-3B23-4F6E-AB34-1694A4077A7C Q26782902-00272F70-078A-4CE9-9A3F-26E7E6C04393 Q26853170-F0CE66D0-4E83-4DF4-B1BC-1C96A3133BC2 Q27003955-0CEBFD93-31B5-4690-BDB4-3909E14AC892 Q28088365-EBFE2AE6-EC50-4E98-8FA0-CFDC69593194 Q30249007-78B82645-D206-4ADE-99C2-2A8CD5C546A4 Q30358639-CCE5C1BE-6D56-4F06-8386-D41CA11CC9EC Q30659342-2F77A9EB-C30F-484B-BF0B-CC3A8C1884B9 Q33387037-5E47EEDA-DD46-4088-9C1E-AFAD9E9BA7CF Q33388648-0D8BB1F1-570F-4AB4-93C1-EC936AF7B0CE Q33393623-9CFD4C54-F86A-40C7-93CC-AB7641983AC8 Q33396036-90747DD1-67D6-4A0F-B2FE-E4C81BCE2052 Q33397302-CD8306F8-B152-4911-9350-D55AF0D145D5 Q33398019-C2D5E335-7ACE-4952-92EE-399593339091 Q33398415-E838D1AB-08D2-4116-A0C7-955AD2699C14 Q33406742-16CD483B-51B7-477C-AB34-3315F2989376 Q33407102-36D1C10C-B5DE-4DFE-A630-7FC73F1B97B9 Q33408772-D403673D-1979-4721-8146-1167E53FBDA9 Q33410282-6A5889C3-8135-4AC1-89AB-B6F7BD51EF02 Q33413210-F7AA2D32-99ED-42F3-90E3-5D0D4DA9C5AE Q33416550-DC88E34A-F418-4C12-BB82-46D49B1C797D Q33418964-A27BE1B9-AD80-424A-8150-B02EEAC85FA6 Q33423873-1EC05125-C644-4617-9EDF-8A2568B790A2 Q33439291-C07355AD-6B0D-45CD-AAD4-A091B561B532 Q33685903-6B0FBDA1-143D-46AA-8C1C-1B8DDAD784B2 Q33817800-E2BD6606-9713-498C-8FA5-2E86F8001532 Q33832087-3A41F6D1-A0CC-4930-895E-A6BEF7887778 Q33874179-BCD406AE-E9C9-494A-AC11-35E968D7F48D Q33911781-67EEABD1-5DD8-4ECB-A8FF-3D5FA2997F5B Q33946396-7B94929B-44E4-4CB3-B79B-A23D378857DB Q33956871-4F679FC8-BAA2-451C-860B-8872F86FC804 Q34173071-EF96FD54-8096-4786-9CCA-DD1FB9F81D88 Q34220013-F7C59744-33A7-42AE-91F6-FEA676824AF7 Q34253548-7B6CE145-CAD0-4EF8-BBD6-947D5AAACAB3

P2860

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33380246

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@ast

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@en

type

label

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@ast

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@en

prefLabel

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@ast

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@en

P1433

Q33380246-0C6E7ABE-614E-407E-B589-312DF10AEAAE

P1476

Q33380246-AFD56D8D-3859-47DA-9872-528A629ACC96

P2093

Q33380246-156A24CF-2AD6-4F23-BAD8-34F5462E0735

Q33380246-17CE4361-E29F-4C62-9E45-B52FABE280A9

Q33380246-21E11CAF-E73F-4D42-ACE0-6EB85A806E13

Q33380246-3C6A258D-79BA-4D81-B8AA-3B1439A8A27B

Q33380246-66F0E9C8-F72C-4D46-9A8B-AAA80C511969

Q33380246-7C2652FF-09C8-40F6-9D51-D3D3BB6433FF

Q33380246-84121DBD-E4A1-4C6F-9544-E23F5F1766F9

Q33380246-8B957B39-00A5-486B-BC04-DEC6C5E17140

Q33380246-915941DE-25B0-48E4-B736-C73E3FE7DABF

Q33380246-A0B513DF-7B44-45B2-9986-75A7F3DD51F0

P304

Q33380246-2C825962-D955-40C5-9A65-723788151996

P31

Q33380246-2CEEC67A-C45C-4B57-AE89-626050E9FD04

P356

Q33380246-6FBCA93D-F8EB-4A52-AF55-7BD293F74281

P407

Q33380246-8E18E1CA-0DC1-4599-BFE8-79FF395D99AA

P433

Q33380246-E9608B37-F066-4B59-8439-E7406C2CE6CC

P478

Q33380246-B3C6383E-8D4E-428E-9006-0AAE9CCD0963

P50

Q33380246-498D7E78-49D6-4D8B-8479-F7CC1D93B037

P577

Q33380246-3336351C-AF2A-4281-B5AD-A18FE9DC028E

P698

Q33380246-553BD7B5-0076-4DB9-BE4D-D65211A63329

P356

JCO.2007.15.3429

P1433

Journal of Clinical Oncology

P1476

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

@en

P2093

Annette Ervin-Haynes

http://www.w3.org/2001/XMLSchema#string

Craig E Cole

http://www.w3.org/2001/XMLSchema#string

Dennis Pietronigro

http://www.w3.org/2001/XMLSchema#string

Glen Justice

http://www.w3.org/2001/XMLSchema#string

Izidore S Lossos

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Joseph M Tuscano

http://www.w3.org/2001/XMLSchema#string

Kenichi Takeshita

http://www.w3.org/2001/XMLSchema#string

Kenton Wride

http://www.w3.org/2001/XMLSchema#string

Kyle McBride

http://www.w3.org/2001/XMLSchema#string

P304

4952-4957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.3429

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18606983

http://www.w3.org/2001/XMLSchema#string